The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by r ...

The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some ...

The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some ...

Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key ...

India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo ...

CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...

Recent developments for the new Standards of Care in Overweight and Obesity guidelines, the first clinical guidance of its kind, were presented during the Standards of Care in Overweight and Obesity ...

In Mexico, brand-name Wegovy can be purchased for around $200 a month. Spotty insurance coverage has helped drive demand for compounded GLP-1 products.

Semaglutide belongs to a class of medications called glucagon-like peptide-1 receptor agonists, or GLP-1s. These prescription drugs mimic the GLP-1 hormone, which is made naturally in the gut.

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.